Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention in ST elevation myocardial infarction
An 83-year-old man with a history of permanent atrial fibrillation (AF) anticoagulated by dabigatran 150 b.i.d., type 2 diabetes mellitus, and hypertension was admitted to the hospital with a diagnosis of ST-elevation myocardial infarction (STEMI). The patient was loaded with 300 mg of aspirin p.o.,...
Saved in:
Main Authors: | Marta Kurdziel, Bartosz Hudzik, Anna Kazik, Jacek Piegza, Janusz Szkodzinski, Mariusz Gąsior |
---|---|
Format: | article |
Language: | EN |
Published: |
Termedia Publishing House
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/a7df0729b45f4279910a8fb9d0024f60 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COVID-19 mimicking ST-elevation myocardial infarction
by: Kamil Bujak, et al.
Published: (2020) -
Percutaneous coronary intervention in the elderly with ST-segment elevation myocardial infarction
by: Gao L, et al.
Published: (2014) -
MRI discriminates thrombus composition and ST resolution after percutaneous coronary intervention in patients with ST-elevation myocardial infarction.
by: Ignasi Barba, et al.
Published: (2011) -
Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction
by: Piotr Desperak, et al.
Published: (2020) -
Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
by: Senta Frol, et al.
Published: (2021)